IC
BLUE

Ikarian Capital’s bluebird bio BLUE Stock Holding History

Ikarian Capital’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,199
Closed -$3.2M – 226
2021
Q1 		$3.2M Hold
8,199
– – 0.11% 166
2020
Q4 		$4.59M Buy
+8,199
New +$5.2M 0.2% 99
2020
Q3 		– Sell
-2,702
Closed -$2.14M – 182
2020
Q2 		$2.14M Sell
2,702
-2,702
-50% -$2.04M 0.17% 105
2020
Q1 		$3.22M Buy
+5,404
New +$5.27M 0.24% 78

Other funds holding BLUE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ikarian Capital's BLUE Position: Q3 2023 in Review

Ikarian Capital sold out of bluebird bio (BLUE) in Q3 2023, closing a stake of 20,631 shares — an estimated $1.36M sold.

Ikarian Capital first reported a position in BLUE in Q1 2020 and held it in 11 quarters. The position peaked at $6.4M in Q2 2020. 168 funds tracked by Wall St. Rank hold BLUE as of Q3 2023.

  • Ikarian Capital reported no remaining bluebird bio position as of Q3 2023 after selling out during the quarter.
  • Ikarian Capital sold 20,631 bluebird bio shares in Q3 2023, an estimated $1.36M.
  • Ikarian Capital first reported a position in bluebird bio in Q1 2020 and held it in 11 quarters.
  • Ikarian Capital's bluebird bio position peaked at $6.4M in Q2 2020.
  • 168 funds tracked by Wall St. Rank held bluebird bio as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.